SYK Stock Recent News
SYK LATEST HEADLINES
Stryker's (SYK) acquisition of care.ai is set to enhance its healthcare IT offerings with AI-assisted virtual care workflows and smart room technology.
Stryker (SYK) announces the launch of its Pangea Plating System, which is likely to provide solutions for internal fixation and stabilization of bone fractures.
Portage, Michigan, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.80 per share payable October 31, 2024 to shareholders of record at the close of business on September 30, 2024, representing an increase of 6.7% versus the prior year and unchanged from the previous quarter.
Medical and surgical products manufacturer Stryker Co. NYSE: SYK is a beneficiary of the acute care boom occurring in the healthcare industry. Acute care is considered short-term intensive hospital-based emergency services that often occur in the emergency department (ED) or intensive care unit (ICU).
Stryker (SYK) completes of the acquisition of MOLLI, a privately held company, to strengthen its commitment to advancing surgical solutions in breast cancer care.
Stryker is a global medical products and devices company that has global operations in over 75 countries. Historically, the company has been a compounder, generating high returns on capital and has put up impressive top and bottom line growth rates. Recent second quarter results showed strong growth in orthopedics and international markets, with a beat on both revenue and EPS.
While the top- and bottom-line numbers for Stryker (SYK) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Stryker (SYK) beats second-quarter earnings estimates, driven by robust sales growth and innovative launches like the LIFEPAK 35 and Spine Guidance 5. The company raises 2024 guidance.
Kevin Lobo, Stryker CEO, joins 'Money Movers' to discuss the company's second quarter earnings as it saw strong demand for surgical procedures and new products.
Here is how Stryker (SYK) and Centessa Pharmaceuticals PLC Sponsored ADR (CNTA) have performed compared to their sector so far this year.